The nanoscale characteristics of Z-M ADCN results in elevating both pharmacokinetics and in vivo targeting performance than those of free ZHER2:342 because there are a number of ZHER2:342 on the nanoagent surface, Z-M ADCN can more effectively accumulate in tumor and be internalized by cancer cells through HER2-specific receptor-mediated endocytosis. The gene discussed is ERBB2; the disease is cancer.